Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 20,671 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Arthritis, Rheumatoid
Interventions: Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine, Stereotactic Body Radiation (SBRT); Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Milwaukee, Wisconsin

Conditions: Glioblastoma
Interventions: Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab; Drug
Lead sponsor: David Peereboom; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Conditions: Type 1 Diabetes
Interventions: interoperable Artificial Pancreas System (iAPS), Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS); Device · Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Santa Barbara, California • Stanford, California • Boston, Massachusetts + 2 more

Conditions: End Stage Renal Disease, Chronic Kidney Diseases
Interventions: Berinert, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hemorrhagic Fever
Interventions: Xpert Hemorrhagic Fever test; Diagnostic Test
Lead sponsor: Cepheid; Industry
Eligibility: 14 Years and older
Enrollment: 725 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neurodegenerative Diseases
Interventions: 123-I INER; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline
Interventions: Nattokinase, Placebo; Dietary Supplement · Other
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 100 Years
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
Interventions: Nicotinamide riboside; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ampulla of Vater Adenocarcinoma, Small Intestinal Adenocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Ampulla of Vater Cancer AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Ampulla of Vater Cancer AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Interventions: Bevacizumab, Capecitabine, Oxaliplatin; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions: Freestyle Libre 3 Continuous Glucose Monitor (CGM); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hairy Cell Leukemia
Interventions: Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab (M1095), Adalimumab, Placebo; Drug · Other
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: exercise; Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: trastuzumab, imatinib mesylate; Biological · Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Renal Failure
Interventions: phlebotomy; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration; Procedure · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection
Interventions: 18F-fluciclovine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more

Conditions: Prediabetes, Type 2 Diabetes
Interventions: Metformin, Liraglutide, Glargine, Placebo; Drug
Lead sponsor: RISE Study Group; Network
Eligibility: 20 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington

Conditions: Infections, Respiratory Syncytial Virus
Interventions: Danirixin, CXCL1; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 64 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions: gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liver Cirrhosis
Interventions: Zibotentan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Interventions: AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more

Search by objective public record fields.

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

The International Diabetes Closed Loop (iDCL) Trial: Protocol 4

Berinert (C1INH) vs Placebo for DGF/IRI

Xpert Hemorrhagic Fever on Edge X in Trained and Untrained Users

Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects

Nattokinase Atherothrombotic Prevention Study

Nicotinamide Riboside in LVAD Recipients

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

A Study of Glycemic Control in Left Ventricular Assist

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients

Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors

18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

RISE Adult Medication Study

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus